Japan Biotechs Focus On Better Treatment For Nation's Hay Fever
This article was originally published in PharmAsia News
Japanese biotechnology companies just starting up business are focusing on treatments for the 20 million people in the country who have hay fever
You may also be interested in...
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.
HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe.